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Past advances in research and modern medicine have helped to produce cures for diseases that used to plague populations, and as a result, life expectancies have increased substantially throughout the years. For example, in East Asia, the average life expectancy has nearly doubled within the last sixty-four years (from 45 years old in 1950 to over 74 years old today). Such statistics often give promise and meaning to the medicinal opportunities offered through scientific research; however, the successes also present new challenges. Neurodegenerative diseases, often developed in the later stages of life, have become increasingly more prevalent, no doubt a direct result of increased longevity, as well as a serious medical and economical challenge to today's society. For example, The World Health Organization projects that neurodegenerative diseases will surpass cancer to become the second leading cause of death by 2040. Therefore, the urgency to understand the fundamentals of neurodegenerative diseases as well as develop diagnostic and therapeutic agents is apparent.
In this themed issue of Chemical Society Reviews on molecular medicine and neurodegenerative diseases, several areas within the neurodegenerative field are explored, including mechanistic/ structural studies of neurodegenerative processes, pathologically relevant biological pathways/factors, as well as the development of chemical tools, diagnostic/ imaging agents, and potential therapeutic agents. By no means is this themed issue comprehensive on neurodegenerative diseases, but researchers new to the field, as well as others actively engaged in this field, will find broad insights into the multifactorial components of Alzheimer's disease (AD). Our hope is that the highlighted works from prominent scientists would stimulate scientists to target their current and future research toward answering some of the critical questions within the field that will be essential to uncovering the pathology of the disease so that possible treatments or therapeutics can be developed.
Neurodegenerative diseases are inherently complex and the disease etiology is not completely understood. Hallmarks of diseases have been identified, such as aggregated misfolded proteins (e.g., amyloid-b, Ab; tau) in AD, yet the roles of these pathological features in disease onset and progression are still unclear. To develop an effective therapeutic, the fundamentals of the disease, such as the correlation of misfolded peptides to neuropathogenesis, need to first be fully revealed.
In the review of ''Disordered amyloidogenic peptides may insert into the membrane and assemble into common cyclic structural motifs'', Jang, Arce, Ramachandran, Kaga, Lal, and Nussinov (DOI: 10.1039/c3cs60459d) provide an overview of the interaction of Ab with cell membranes contributing to cellular dysfunction. From this review, the readers will gain insights into aspects of the disease, such as a proposed mechanism of Ab toxicity, through various conformational structures, particularly oligomers, of the Ab peptide that could form amyloid channels within the membrane, ultimately leading to the loss of ionic homeostasis within the cell that directs cell death.
Moreover, Kotler, Walsh, Brender, and Ramamoorthy (DOI: 10.1039/ c3cs60431d) offer an additional view on the interrelationship between Ab peptides and cellular membranes as a potential underlying cause of toxicity. More interestingly, the authors present further perspective on the influence of gangliosides, molecules composed of a glycosphingolipid with one or more sialic acids conjugated with the sugar chain, on Ab aggregation pathway and Ab-promoted membrane disruption.
Other components, such as cholesterol, are important to consider when evaluating the interaction between Ab and cell membranes. Lee, Korshavn, Kochi, Derrick, and Lim (DOI: 10.1039/c4cs00005f), in their tutorial review, briefly describe the function of cholesterol in normal biological settings as well as its possible contribution to AD etiology. Furthermore, they also discuss an additional pathological factor to AD (i.e., metals) with its possible interconnection to cholesterol in AD pathogenesis. Barnham and Bush (DOI: 10.1039/ c4cs00138a) illustrate how the dyshomeostasis of essential biometals is associated with age-related neurodegenerative disorders (i.e., AD, Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS)). This review also provides insight into therapeutic strategies that focus on targeting metal homeostasis.
Examination of the peptide itself and its processing pathways can prove to be as important as investigating the relationship between amyloidogenic peptides and cell membranes. Posttranslational modification of both amyloid precursor protein (APP; forms Ab after proteolytic cleavage by b-secretase (BACE1) and g-secretase) and tau by addition of O-linked N-acetylglucosamine (O-GlcNAc) is illustrated in the review article by Yuzwa and Vocadlo (DOI: 10.1039/c4cs00038b). The authors summarize the biochemical role of O-GlcNAc and its link to tau/APP in AD. Potential protective effects have been demonstrated upon increased O-GlcNAc levels in the brain of AD mouse models, suggesting a new avenue of investigations to better understand the pathogenesis of this disorder.
As the mechanisms of the underlying factors that lead to neurodegeneration become more transparent, advancements in the construction of therapeutic agents must also be made in parallel to ultimately cure the diseases. Current treatments targeting acetylcholinesterase and N-methyl-D-aspartate (NMDA) receptor only alleviate symptoms, thus suggesting the need for additional drug targets and drug discovery approaches. In ''BACE1 (b-secretase) inhibitors for the treatment of Alzheimer's disease,'' Ghosh and Osswald (DOI: 10.1039/ c3cs60460h) outline the evolution of the various chemotypes of BACE1 inhibitors, which have emerged in hopes of targeting BACE1 as an AD treatment due to BACE1's direct connection with Ab generation. Early work on developing aspartyl protease transition state analog peptidomimetic inhibitors is covered as well as the more recent design of nonpeptide structural classes with heterocyclic scaffolds. In both cases, the review highlights examples where structurebased drug design plays a key role in inhibitor design. Several companies have advanced BACE inhibitors into clinical trials and the results are eagerly awaited.
In addition to the presence of aggregated misfolded proteins, an oxidative stress environment is often observed in AD-afflicted brains. As reviewed in ''Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain'' (DOI: 10.1039/c3cs60467e), Mukherjee, Cinelli, Kang, and Silverman picture the role of nitric oxide (NO) in neuronal function as well as in neurodegeneration. Evidence links the dysregulation of nitrergic signaling, the overexpression of neuronal NO synthase (nNOS), and oxidative stress with neurodegeneration, implicating nNOS as a viable therapeutic target. The authors further discuss unique approaches for fashioning small molecules as nNOS inhibitors.
To date most researchers have taken a target-based approach in efforts to identify new therapies for neurodegenerative diseases. Pieper, McKnight, and Ready (DOI: 10.1039/c3cs60448a) provide a compelling example highlighting the potential power of phenotypic screening for neurodegenerative diseases. They present the discovery of a series of neuroprotective small molecules from an in vivo screen of hippocampal neurogenesis by monitoring the incorporation of bromodeoxyuridine (BrdU) into new synthesized DNA to label newly formed neurons within the dentate gyrus. This allowed them to find compounds that increased either proliferation or survival of hippocampal neural precursor cells. The P7C3 class of compounds (an aminopropyl carbazole, designated P7C3) was identified from this screen and the druglike properties were optimized through a series of medicinal chemistry efforts. These optimized compounds showed neuroprotective activity in animal models of PD, ALS, traumatic brain injury (TBI), retinal degeneration, and age-related cognitive decline, and efforts are underway to more fully understand the mechanism of action.
Manipulation of the endocannabinoid system could provide an alternative means to impact various neurodegenerative diseases. As reviewed by Konz and Nomura (DOI: 10.1039/c4cs00047a), the inhibition of monoacylglycerol lipase (MAGL), a 2-AG-degrading enzyme, has shown anti-inflammatory and neuroprotective effects in AD/PD mouse models. Furthermore, anti-amyloidogenic properties of MAGL inhibitors have been indicated, which implies another possible arsenal to combat neurodegenerative diseases.
In order to diagnose the status and progression of neurodegenerative disorders with and without treatment, single photon computed tomography (SPECT) or positron emission computed tomography (PET) has been the forerunner for molecular imaging. In ''PET/SPECT imaging agents for neurodegenerative diseases,'' Zhu, Ploessl, and Kung (DOI: 10.1039/c3cs60430f) describe a field of radiopharmaceuticals, examining the different isotopes for PET/SPECT imaging; focusing on imaging agents currently employed for AD and PD, as well as the future prospects for expanding imaging targets for these diseases. Hayne, Lim,
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